Frazier Life Sciences Management’s Chinook Therapeutics KDNY Stock Holding History
Bought
Maintained
Sold
Frazier Life Sciences Management's KDNY Position: Q3 2023 in Review
Frazier Life Sciences Management sold out of Chinook Therapeutics (KDNY) in Q3 2023, closing a stake of 4,345,559 shares — an estimated $167M sold.
Frazier Life Sciences Management first reported a position in KDNY in Q1 2022 and held it in 6 quarters. The position peaked at $167M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Frazier Life Sciences Management reported no remaining Chinook Therapeutics position as of Q3 2023 after selling out during the quarter.
- Frazier Life Sciences Management sold 4,345,559 Chinook Therapeutics shares in Q3 2023, an estimated $167M.
- Frazier Life Sciences Management first reported a position in Chinook Therapeutics in Q1 2022 and held it in 6 quarters.
- Frazier Life Sciences Management's Chinook Therapeutics position peaked at $167M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics as of Q3 2023.
Based on Frazier Life Sciences Management's 13F filing for Q3 2023, filed 14 Nov 2023.